Navigation Links
OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
Date:4/15/2008

AMSTERDAM, April 15 /PRNewswire/ -- SynCo Bio Partners B.V., a leading GMP biopharmaceutical manufacturer, has signed a Master Services Agreement with OncoMed Pharmaceuticals, a company developing novel therapeutics that target cancer stem cells. Under the agreement, SynCo will fill and finish batches of OncoMed's lead product, antibody OMP-21M18, for use in Phase I clinical trials.

Announcing the agreement, Pierre Warffemius, CEO, said, "We are delighted that a company at the forefront of cancer therapies has recognised our expertise in biopharmaceutical processing by choosing us to fill their lead antibody for early clinical trails."

Paul J. Hastings, President and CEO of OncoMed, "We selected SynCo Bio Partners because we needed a GMP-accredited contract manufacturing organisation that had a proven track record in filling biologics. With SynCo's expertise in all aspects of biopharmaceutical manufacture, they were an ideal partner for us at this crucial stage in our development."

OncoMed recently announced that it had signed a worldwide strategic alliance with GSK to develop cancer stem cell antibody therapeutics. One of the key projects in this alliance will be the development of OncoMed's lead antibody product candidate, OMP-21M18, a monoclonal antibody, which is scheduled to enter the clinic in 2008.

SynCo will fill and finish antibody OMP-21M18 at its Amsterdam-based facility. This facility is able to fill a wide range of biopharmaceuticals into vials, including protein, polysaccharide, and live-microbial-based products using the latest filling and finishing equipment.

Issued on behalf of SynCo Bio Partners by De Facto Communications

About SynCo Bio Partners B.V.

SynCo Bio Partners is a GMP-licensed bulk drug substance and final product CMO with in-depth clinical and commercial production experience with mammalian and microbial systems. This experience has been acquired by developing new production processes for a number of international clients and producing a wide variety of different vaccines, live bacterial products and recombinant proteins in our state-of-the-art, GMP-licensed facilities in the last seven years.

Financially stable and focused solely on biopharmaceuticals, SynCo Bio Partners acts as a strategic, long-term partner delivering your product on time and to the highest quality standards. All our staff are committed to exceeding customer expectations and believe that taking a truly collaborative approach to manufacture is the key to a successful outcome.

About OncoMed Pharmaceuticals Inc.

OncoMed Pharmaceuticals is discovering and developing novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and metastases. The company has established a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such as breast, colon, prostate, and lung cancers. OncoMed is a leader in cancer stem cell research and the identification of novel cancer stem cell targets. Privately-held, the company's investors include US Venture Partners, Latterell Venture Partners, Morgenthaler Ventures, The Vertical Group, Adams Street Partners, De Novo Ventures and Bay Partners. Additional information can be found at the company's website: http://www.oncomed.com.


'/>"/>
SOURCE SynCo Bio Partners B.V.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
5. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
6. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
7. UNICEF Partners With Causes on Facebook to Launch Charity Gift Feature
8. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
9. iCAD Announces Partnership for Initiating Clinical Testing of Its Virtual Colonoscopy CAD Product
10. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
11. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Calif. , Feb. 23, 2017 ... company focused on the development and commercialization of ... pain, announced that it will release fourth quarter ... Thursday, March 2nd, 2017. AcelRx management will host ... Time (1:30 p.m. Pacific Time) on March 2 ...
(Date:2/23/2017)... 2017 Obese people are seldom ... varicose veins in their body. The rising number of ... adoption of endovenous laser therapy for treatment of varicose ... therapy market, published by Future Market Insights, indicates ... consequences of obesity have collectively factored the growth in ...
(Date:2/23/2017)... , Feb 23, 2017 Research and ... Analysis & Trends - Industry Forecast to 2025" report to ... ... of around 6.9% over the next decade to reach approximately $47.6 ... market estimates and forecasts for all the given segments on global ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... 2017 , ... The 89th Academy Awards will be celebrated this weekend, which ... Center Bunkum Award. We invite you to enjoy our 11th annual tongue-in-cheek “salute” to ... the Center for American Progress (CAP), for its report, Lessons From State Performance on ...
(Date:2/23/2017)... ... 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased to announce ... a longtime supporter of the event. , "We are pleased that KLS Martin is ... Havlik, 2017 ACPA President. "KLS Martin has a long track record of support of ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... leadership , media relations, content marketing, social media management, corporate communications, SEO and ... in the state and in nearby New Hampshire, Massachusetts and Canada, Rosica will ...
(Date:2/23/2017)... ... , ... Dr. David Mahon leads Siena Dental, a comprehensive dental practice located ... 2017 Top Patient Rated Henderson Dentist by Find Local Doctors earlier this ... and dentists who have earned high ratings and superior patient reviews from multiple credible ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... today that it will soon begin franchising throughout the U.S. starting this spring. ... help bring the practice of meditation mainstream. Current Meditation will be the first ...
Breaking Medicine News(10 mins):